These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

445 related items for PubMed ID: 17629847

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Monitoring direct FXa-inhibitors and fondaparinux by Prothrombinase-induced Clotting Time (PiCT): relation to FXa-activity and influence of assay modifications.
    Harder S, Parisius J, Picard-Willems B.
    Thromb Res; 2008; 123(2):396-403. PubMed ID: 18571698
    [Abstract] [Full Text] [Related]

  • 3. Assessment of laboratory assays to measure rivaroxaban--an oral, direct factor Xa inhibitor.
    Samama MM, Martinoli JL, LeFlem L, Guinet C, Plu-Bureau G, Depasse F, Perzborn E.
    Thromb Haemost; 2010 Apr; 103(4):815-25. PubMed ID: 20135059
    [Abstract] [Full Text] [Related]

  • 4. Monitoring high-dose heparinization during cardiopulmonary by-pass--a comparison between prothrombinase-induced clotting time (PiCT) and two chromogenic anti-factor Xa activity assays.
    Raivio P, Kuitunen A, Petäjä J, Ilveskero S, Lassila R.
    Thromb Haemost; 2008 Feb; 99(2):427-34. PubMed ID: 18278195
    [Abstract] [Full Text] [Related]

  • 5. Prothrombinase-induced clotting time assay for determination of the anticoagulant effects of unfractionated and low-molecular-weight heparins, fondaparinux, and thrombin inhibitors.
    Calatzis A, Peetz D, Haas S, Spannagl M, Rudin K, Wilmer M.
    Am J Clin Pathol; 2008 Sep; 130(3):446-54. PubMed ID: 18701419
    [Abstract] [Full Text] [Related]

  • 6. Heptest-STAT, a new assay for monitoring of low-molecular-weight heparins, is not influenced by pregnancy-related changes of blood plasma.
    Dempfle CE, Zharkowa U, Elmas E, Ahmad-Nejad P, Neumaier M, Borggrefe M.
    Thromb Haemost; 2009 Nov; 102(5):1001-6. PubMed ID: 19888540
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Preincubation in the Prothrombinase-induced Clotting Time test (PiCT) is necessary for in vitro evaluation of fondaparinux and to be avoided for the reversible, direct factor Xa inhibitor, rivaroxaban.
    Kluft C, Meijer P, Kret R, Burggraaf J.
    Int J Lab Hematol; 2013 Aug; 35(4):379-84. PubMed ID: 23151091
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Heparin chain-length dependence of factor Xa inhibition by antithrombin in plasma.
    Rezaie AR.
    Thromb Res; 2007 Aug; 119(4):481-8. PubMed ID: 16515805
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. The correlation between plasma anti-factor Xa activity and haemostatic tests in healthy dogs, following the administration of a low molecular weight heparin.
    Mischke R, Grebe S.
    Res Vet Sci; 2000 Dec; 69(3):241-7. PubMed ID: 11124095
    [Abstract] [Full Text] [Related]

  • 13. EP217609, a neutralisable dual-action FIIa/FXa anticoagulant, with antithrombotic effects in arterial thrombosis.
    Alame G, Mangin PH, Freund M, Riehl N, Magnenat S, Petitou M, Hechler B, Gachet C.
    Thromb Haemost; 2015 Feb; 113(2):385-95. PubMed ID: 25374268
    [Abstract] [Full Text] [Related]

  • 14. The uncalibrated prothrombinase-induced clotting time test. Equally convenient but more precise than the aPTT for monitoring of unfractionated heparin.
    Korte W, Jovic R, Hollenstein M, Degiacomi P, Gautschi M, Ferrández A.
    Hamostaseologie; 2010 Nov; 30(4):212-6. PubMed ID: 21057708
    [Abstract] [Full Text] [Related]

  • 15. Factor Xa-activated whole blood clotting time (Xa-ACT) for bedside monitoring of dalteparin anticoagulation during haemodialysis.
    Frank RD, Brandenburg VM, Lanzmich R, Floege J.
    Nephrol Dial Transplant; 2004 Jun; 19(6):1552-8. PubMed ID: 15034159
    [Abstract] [Full Text] [Related]

  • 16. Relative neutralization of the biological actions of sulfaminoheparosans (K5 derivatives) and heparins by protamine sulfate.
    Maddineni J, Hoppensteadt DA, Cornelli U, Manoni M, Fareed J.
    Clin Appl Thromb Hemost; 2007 Jan; 13(1):52-64. PubMed ID: 17164496
    [Abstract] [Full Text] [Related]

  • 17. Clinical evaluation of a new one-stage clotting assay for heparin and low molecular weight heparins.
    Harenberg J.
    J Mal Vasc; 1987 Jan; 12 Suppl B():68-70. PubMed ID: 2834495
    [Abstract] [Full Text] [Related]

  • 18. Effect of tissue factor pathway inhibitor (TFPI) in the HEPTEST assay and in an amidolytic anti factor Xa assay for LMW heparin.
    Kristensen HI, Ostergaard PB, Nordfang O, Abildgaard U, Lindahl AK.
    Thromb Haemost; 1992 Sep 07; 68(3):310-4. PubMed ID: 1332210
    [Abstract] [Full Text] [Related]

  • 19. In vitro study of the anticoagulant effects of edoxaban and its effect on thrombin generation in comparison to fondaparinux.
    Samama MM, Mendell J, Guinet C, Le Flem L, Kunitada S.
    Thromb Res; 2012 Apr 07; 129(4):e77-82. PubMed ID: 21851967
    [Abstract] [Full Text] [Related]

  • 20. The PiCT® test is a reliable alternative to the activated partial thromboplastin time in unfractionated heparin therapy management: results from a multicenter study.
    Brisset AC, Ferrández A, Krause M, Rathbun S, Marlar R, Korte W.
    J Thromb Haemost; 2016 Nov 07; 14(11):2187-2193. PubMed ID: 27582411
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 23.